Italy’s medicines regulator has given the go-ahead for human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may help reduce COVID-19 symptoms and make patients less infectious.

The drug was identified as a potential COVID-19 treatment by the use of supercomputers to screen more than 400,000 molecules for chemical characteristics that might inhibit the virus, focusing on those already approved for use in humans.